Evidence map›Paper›PMID 38990451›Full record

ArticleInvestigational new drugs2024

Phase I study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer.

Jing Zhang, Wenwei Yang, Junbao Liu, Nan Wang, Zhaoying Ren, Tingting Yang, Gongli Xie, Guifu Wu, Yongkun Sun

Abstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jing Zhang *Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Chaoyang District Panjiayuan Nanli No. 17, Beijing, 100021, China.
Wenwei Yang *Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Chaoyang District Panjiayuan Nanli No. 17, Beijing, 100021, China.
Junbao LiuDepartment of Medical Oncology, Beijing Chaoyang District Sanhuan Cancer Hospital, Chaoyang District Shilihe No.352, Beijing, 100122, China.
Nan WangDepartment of Medical Oncology, Beijing Chaoyang District Sanhuan Cancer Hospital, Chaoyang District Shilihe No.352, Beijing, 100122, China.
Zhaoying RenDepartment of Medical Oncology, Beijing Chaoyang District Sanhuan Cancer Hospital, Chaoyang District Shilihe No.352, Beijing, 100122, China.
Tingting YangDepartment of Medical Oncology, Beijing Chaoyang District Sanhuan Cancer Hospital, Chaoyang District Shilihe No.352, Beijing, 100122, China.
Gongli XieDepartment of Medical Oncology, Beijing Chaoyang District Sanhuan Cancer Hospital, Chaoyang District Shilihe No.352, Beijing, 100122, China.
Guifu WuDepartment of Medical Oncology, Beijing Chaoyang District Sanhuan Cancer Hospital, Chaoyang District Shilihe No.352, Beijing, 100122, China. 414237191@qq.com.
Yongkun SunDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Chaoyang District Panjiayuan Nanli No. 17, Beijing, 100021, China. hsunyk@cicams.ac.cn.

Funding

Beijing Hope Run Special Fund of Cancer Foundation of China LC2022A10Spark Plan XH-B051
6 · The paper itself

Abstract

purposeThis phase I trial is to determine the recommended dose of the TAS-102, irinotecan plus bevacizumab regimen and assess its safety and efficacy in patients with metastatic colorectal cancer refractory to fluoropyrimidine and oxaliplatin treatment.

methodsA 3 + 3 designed dose escalation was performed. Patients were administered TAS-102 (30-35 mg/m

resultsEighteen patients were enrolled: 6 at the Level 1 (TAS-102 30 mg/m

conclusionThe regimen of TAS-102, irinotecan, and bevacizumab is tolerable with antitumor activity for metastatic colorectal cancer patients refractory to first-line fluoropyrimidines and oxaliplatin treatment.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBevacizumabColorectal NeoplasmsIrinotecanPyrrolidinesThymineTrifluridineAdultAgedDrug CombinationsFemaleHumansMaleMiddle AgedNeoplasm MetastasisUracilBevacizumabDrug CombinationsIrinotecanPyrrolidinesThymineTrifluridinetrifluridine tipiracil drug combinationUracilBevacizumabIrinotecanMetastatic colorectal cancer (mCRC)Second-line therapyTrifluridine/tipiracil (TAS-102)

Identifiers

PMID38990451

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.